Eno1, also known as α -Enolase or 2 -phospho -D -glycerate hydrolase, is a glycolytic enzyme. It catalyzes the conversion of 2 -phosphoglyceric acid to phosphoenolpyruvic acid during glycolysis, playing a crucial role in energy metabolism. It is a multifunctional oncoprotein present in the cell surface and cytoplasm, involved in multiple cancer-related pathways, and is of great significance in cancer research. Genetic models, such as KO/CKO mouse models, can provide valuable insights into its functions [1,6].

In cancer research, knockdown of Eno1 in lung cancer cell lines decreased cancer cell proliferation and invasiveness, while overexpression enhanced these processes, indicating its role in lung cancer metastasis [5]. In liver cancer, Eno1 promotes carcinogenesis through YAP1-dependent arachidonic acid metabolism [2]. Inhibiting Eno1 in hypoxic pulmonary hypertension restored endothelial dysfunction, suggesting its contribution to this disease [3]. Eno1 also suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1 in hepatocellular carcinoma cells [4].

In conclusion, Eno1 is a key glycolytic enzyme with multifaceted functions. Its dysregulation is associated with various diseases, especially cancers. Studies using KO/CKO mouse models and other loss-of-function experiments have revealed its roles in cancer metastasis, carcinogenesis, and other disease-related biological processes, providing important clues for understanding disease mechanisms and developing potential therapies.